05:08am Tuesday 12 December 2017

Penn Study Examines Patients' Perspectives on Deactivation of Implantable Defibrillators in End-of-Life Scenarios

CHICAGO – Most patients with implantable cardioverter defibrillators (ICDs)—small devices placed in a person’s chest to help treat irregular heartbeats with electrical pulses, or shocks—haven’t thought about device deactivation if they were to develop a serious illness from which they were not expected to recover.  But given changes in healthcare, there may be a new reason to do so.  A new study led by researchers in the Perelman School of Medicine at the University of Pennsylvania, which was presented today at the 2014 Scientific Sessions of the American Heart Association, investigated patient perspectives on deactivation of these devices at the end of life, especially related to decisions to deactivate devices against patient or family wishes.

“During a time of scrutiny about life-prolonging efforts that may be seen as too costly or medically futile, end-of-life planning is an important topic for patients with ICDs to address with their doctors and family,” said senior study author James N. Kirkpatrick, MD, assistant professor in the division of Cardiovascular Medicine and department of Medical Ethics and Health Policy at Penn. “This study provides important insight into patient perspectives around the controversial concept of clinicians deactivating these devices against patient and family wishes. It has been argued that decisions not to perform CPR on patients, even if they want it, is ethically justified in cases of medical futility. If an ICD is a form of resuscitation, it could be argued that defibrillators can be deactivated under similar circumstances.”

The study’s researchers interviewed 60 patients with ICDs or cardiac resynchronization therapy ICDs (CRT-Ds) at the outpatient electrophysiology practice at the Hospital of the University of Pennsylvania between Summer 2012 and Summer 2013. The survey questions addressed: the inclusion of ICD deactivation in advanced directives; whether ICD deactivation is physician-assisted suicide; and whether unilateral ICD deactivation can be ethically justified.

According to the study’s results, only 15 percent of patients had thought about device deactivation if they were to develop a terminal illness. A small majority of patients (53 percent) had advanced directives, but only one mentioned what to do with the device at the end of life. In addition, only 3 percent of patients had discussed device management with their clinicians. However, the majority of patients did not believe that device deactivation in accordance with patient wishes was physician-assisted suicide (78 percent), but did believe that it was not ethical/moral for doctors to deactivate ICDs against patients’ wishes (78 percent).

Previous studies have focused on health providers’ and patients’ perspectives on ICD deactivation, but this is the first to explore perspectives on deactivation against patient and family wishes. “There’s definitely a disconnect between the number of people who have ICDs and those who’ve seriously considered the issues surrounding deactivation of the devices in end-of-life scenarios,” said Kirkpatrick. “Additional studies are needed to further explore the ethical issues involved and how definitions and concepts of medical futility are communicated to patients and families.”

Other authors from Penn include Margaret G. Daeschler and Ralph J. Verdino, MD.  

NOTE: These findings are being presented as Abstract #9923 with the following title: The Ethics of Unilateral ICD and CRT-D Deactivation: Patient Perspectives.

###

Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report‘s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2013 fiscal year.

The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania — recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital — the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2013, Penn Medicine provided $814 million to benefit our community.


Share on:
or:

MORE FROM Heart disease

Health news